Claudia Schoch mainly focuses on Myeloid leukemia, Leukemia, Internal medicine, Cytogenetics and Cancer research. Claudia Schoch interconnects Myeloid, Molecular biology, BAALC and Bone marrow in the investigation of issues within Myeloid leukemia. Her Leukemia research incorporates themes from Immunophenotyping and Gene, Chromosomal translocation.
Her Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Surgery, Oncology and Pathology. Her study in Cytogenetics is interdisciplinary in nature, drawing from both Gene chip analysis, Hematology, Gene rearrangement and Bioinformatics. Her Cancer research study combines topics from a wide range of disciplines, such as Mutation, Fluorescence in situ hybridization and ABL.
Myeloid leukemia, Internal medicine, Leukemia, Molecular biology and Oncology are her primary areas of study. Her Myeloid leukemia study incorporates themes from Myeloid, Karyotype and Cytogenetics. Her studies deal with areas such as Gastroenterology and Pathology as well as Internal medicine.
Her Leukemia study which covers Gene expression profiling that intersects with DNA microarray, Bioinformatics, Computational biology and Gene chip analysis. In her study, which falls under the umbrella issue of Molecular biology, Chronic lymphocytic leukemia is strongly linked to Fluorescence in situ hybridization. The study incorporates disciplines such as Daunorubicin, Survival rate, Surgery and Disease in addition to Oncology.
The scientist’s investigation covers issues in Myeloid leukemia, Molecular biology, Cancer research, Internal medicine and Genetics. She does research in Myeloid leukemia, focusing on Imatinib specifically. Her Molecular biology research incorporates elements of Chromosome, Gene, Karyotype, Chromosomal translocation and Leukemia.
Her work carried out in the field of Leukemia brings together such families of science as Myeloid, Transcription factor, SNP and Mutation. Her Cancer research research is multidisciplinary, incorporating perspectives in DNA microarray, Microarray analysis techniques and Cytogenetics. Her Internal medicine research integrates issues from Surgery and Oncology.
Her scientific interests lie mostly in Myeloid leukemia, Molecular biology, Cancer research, Genetics and Leukemia. Her Myeloid leukemia research includes themes of Fluorescence in situ hybridization and Oncology. She has included themes like Myeloid and SNP in her Molecular biology study.
Her research investigates the connection between Cancer research and topics such as Cytogenetics that intersect with problems in Asparagine and CEBPE. In general Genetics, her work in Gene, Histone, Acute leukemia and Chromosomal rearrangement is often linked to Methyltransferase linking many areas of study. As part of the same scientific family, Claudia Schoch usually focuses on Leukemia, concentrating on Chromosomal translocation and intersecting with Core binding factor acute myeloid leukemia and Receptor tyrosine kinase.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Susanne Schnittger;Claudia Schoch;Martin Dugas;Wolfgang Kern.
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
A. Hochhaus;S. Kreil;A. S. Corbin;P. La Rosée;P. La Rosée.
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Susanne Schnittger;Claudia Schoch;Wolfgang Kern;Cristina Mecucci.
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Thomas Pabst;Beatrice U. Mueller;Nari Harakawa;Claudia Schoch.
Nature Medicine (2001)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
Susanne Schnittger;Tobias M. Kohl;Torsten Haferlach;Wolfgang Kern.
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Thomas Büchner;Wolfgang Hiddemann;Bernhard Wörmann;Helmut Löffler.
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases
Claudia Schoch;Susanne Schnittger;Mirjam Klaus;Wolfgang Kern.
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
C Schoch;S Schnittger;S Bursch;D Gerstner.
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML
S Schnittger;U Kinkelin;C Schoch;A Heinecke.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
Wolfgang Kern;Torsten Haferlach;Claudia Schoch;Helmut Löffler.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: